Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Leases (2021 - 2025)

Historic Capital Leases for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $122000.0.

  • Aligos Therapeutics' Capital Leases fell 3510.64% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $122000.0, marking a year-over-year decrease of 3510.64%. This contributed to the annual value of $122000.0 for FY2024, which is 4718.61% down from last year.
  • Aligos Therapeutics' Capital Leases amounted to $122000.0 in Q3 2025, which was down 3510.64% from $122000.0 recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Capital Leases peaked at $261000.0 during Q4 2021, and registered a low of $53000.0 during Q3 2021.
  • Moreover, its 5-year median value for Capital Leases was $188000.0 (2023), whereas its average is $175421.1.
  • In the last 5 years, Aligos Therapeutics' Capital Leases surged by 22830.19% in 2022 and then plummeted by 4718.61% in 2024.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Capital Leases stood at $261000.0 in 2021, then decreased by 11.88% to $230000.0 in 2022, then increased by 0.43% to $231000.0 in 2023, then plummeted by 47.19% to $122000.0 in 2024, then changed by 0.0% to $122000.0 in 2025.
  • Its Capital Leases stands at $122000.0 for Q3 2025, versus $122000.0 for Q2 2025 and $122000.0 for Q1 2025.